

FC Core Team 2004 - 2005 Project / Process Priorities

Client-Attorney Privileged Work Product; Do not copy or distribute

Strategy /BCY's	Project & Processes
Command the science: exposure, analytical, fate, effects, human health and ecological	Develop and maintain internal 3M analytical capability - telomers and ECF chemistries
	Develop strategy for external science with respect to telomers and ECF chemistries
	Understand TFA risk assessment work
	Develop and implement a 3M Publication Plan: Research to be published as completed in open scientific literature - health research
	Develop and implement a 3M Publication Plan: Research to be published as completed in open scientific literature - environmental.
	Create a process to track global FC related work outside of 3M (Public universities, government institutes, etc.,including literature and funding). Develop process to monitor scientific literature for new data with respect to health effects and environmental issues
	Track developments of biomonitoring by Centers for Disease Control (CDC).
	If necessary, hold workshop for third party spokespersons and include preparation for Science Advisory Panel public meetings -
	Revisit 3M Scientific Advisory Board: Define role, if any, of 3M SAB in the EPA PFOA risk assessment and PFOS IRIS processes.
	Develop strategy to present to EPA SAB on PFOA risk assessment. Include industry team.
	Reestablish international regulatory-scientific-legal-public affairs infrastructure-identify resources, responsibilities and relationships to US Core Team.
	Track agendas for, be aware of and participate in science and regulatory conferences.
	Develop strategy to build stronger (International) OUS science representation at the Research Science Level
	Develop strategy to build stronger (International) OUS science representation at the Science Policy Level
	Develop and implement a program to understand the toxicology and environmental mechanisms for support of the PFOS, PFOA,
	Review the adequacy of the epidemiology data and address any gaps.
	Evaluate PFOA precursors in other products, if any.
	Review the adequacy of the biomonitoring data and address any gaps.

1964.0001

**Exhibit
1964**

State of Minnesota v. 3M Co.,
Court File No. 27-CV-10-28862

Achieve neutral to positive regulatory agency outcomes: findings and actions	Develop an Asian strategy for PFOS regulation, Japan being first.
	Develop an Asian strategy for PFOA regulation, Japan being first.
	Develop an EU strategy for PFOS science policy
	Develop an EU strategy for PFOA science policy
	Ensure sound science and appropriate risk management at EU level by staying engaged with UK-DEFRA Risk Reduction Strategy
	Canada - PFOS Environmental Assessment: Continue to maintain good relations with Environment Canada through regular contacts and strive to ensure that the final assessment - and any actions based thereon - are accurate and fair.
	OECD: Continue to monitor OECD for further regulatory developments.
	United Nations Environmental Programme (UNEP): Continue to monitor UNEP activities for further PFOS/PFOA-related
	Track Activities of Sweden Chemicals Inspectorate. Ensure sound science and appropriate risk management by staying engaged with
	Review historical use of IRIS reviews by international, national, state and local authorities. Look at related cases (e.g. PCB's) and
	Monitor (US) federal and state legislative and regulatory activities related to FC's. Biomonitoring bill in CA, etc.
	Prepare and submit final perfluorooctanyl phase-out summary to EPA when 3M inventories are substantially expired.
	Establish and strengthen dialogue with EPA's ORD (Dr. Preuss) and management (C. Auer, S. Johnson) and other parties outside EPA who will be influential in PFOS and PFOA risk assessment processes and other science policy matters affecting FC's.
	US political strategy: Update the political strategy document and key contacts listing and implement agreed plan.
Satisfy C8 regulatory commitments	Satisfy 3M letter of Intent (LOI) commitments
	Satisfy Dyneon letter of Intent (LOI) commitments
	Society of Plastics Industry (SPI): Work successfully with FMG and SPI to complete ECA negotiations and implement LOI/ECA commitments.
	Support Association of Plastics Manufacturers in Europe (APME) toxicology and environmental study programs.
	Set up internal management review for Decatur site monitoring issues.
	Set up internal management review for Gendorf site monitoring issues.
	Set up internal management review for Cottage Grove site monitoring issues.
	Satisfy MOU Process - 3M Site Monitoring - PFOA
	Antwerp groundwater/site assessment: Complete risk assessment.
	Cottage Grove-Drinking Water (MN Dept. of Health): Determine monitoring and process control requirements.
	Complete 8(e) Self Disclosure and settlement Phase IV audit.

Monitor and prioritize external trends and organizations affecting FC's	Monitor and understand future direction (globally) of NGO's and partnerships.
Effective communication.	Media attention to PFOA Risk Assessment/SAB Review: Work with industry group to take the lead on defense of PFOA and science. Maintain preparedness in order to respond to PFOA media coverage of risk assessment. Maintain talking points for ECA/LOI and other US regulatory activities. Maintain 3M Sumitomo talking points for PFOA / SAB. Develop a message testing mechanism for talking points - particularly in Europe Maintain talking points: C4 chemistry. Maintain talking points: 8(e) voluntary compliance audit. Maintain talking points: Decatur litigation.
Assure FC Enterprise Risk Management organizational health.	Conduct a resource review (current and prospective) for ongoing issue management needs.
C4 Regulatory and Product Stewardship Strategy	Maintain dialogue with EPA and international regulators on C4 chemistry. consent orders at the earliest possible time. Include EPA / NTP class study activity. Catalog all current 3M C4 product applications. Process and control plan needed. Review the adequacy of the C4 polymer degradation data and address any gaps. Evaluate scenarios for full commercialization of PFBS (modelling project) Develop a reference dose for C4 to determine if environmental/biomonitoring need to be done. Improve review process of all C4 commercialization efforts in 3M.
Continue phaseout trajectory (C8 use/emission/exposure reduction)	Prepare a summary of existing perfluorooctanyl inventories across 3M's business units and establish timetables for consumption or use of inventories. Review PFOS exposure assessments and related information. Develop strategy about monitoring of possible source areas, based on existing PFOS exposure assessments and modelling.